Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
01
2021
accepted:
23
03
2021
entrez:
14
5
2021
pubmed:
15
5
2021
medline:
8
10
2021
Statut:
epublish
Résumé
Circulating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤57%. Consecutive HF outpatients were included from May-2006 to February-2016. The primary endpoint was the composite of all-cause death or HF hospitalization and the main secondary endpoint was the composite of cardiovascular death or HF hospitalization. For the later competing risk methods were used. sNEP was measured in 1428 patients (age 67.7±12.7, 70.3% men, LVEF 35.8% ±14), 144 of which had a LVEF >57%. sNEP levels did not significantly differ between LVEF groups (p = 0.31). During a mean follow-up of 6±3.9 years, the primary endpoint occurred in 979 patients and the secondary composite endpoint in 714 (in 111 and 84 of the 144 patients with LVEF >57%, respectively). sNEP was significantly associated with both composite endpoints. Age- and sex- adjusted Cox regression analyses showed higher hazard ratios for sNEP in patients with LVEF >57%, both for the primary (HR 1.37 [1.16-1.61] vs. 1.04 [0.97-1.11]) and the secondary (HR 1.38 [1.21-1.55] vs. 1.11 [1.04-1.18]) composite endpoints. sNEP prognostic value in patients with HF and LVEF >57% outperforms that observed in patients with lower LVEF. Precision medicine using sNEP may identify HF patients with preserved LVEF that may benefit from treatment with sacubitril/valsartan.
Sections du résumé
BACKGROUND
Circulating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤57%.
METHODS
Consecutive HF outpatients were included from May-2006 to February-2016. The primary endpoint was the composite of all-cause death or HF hospitalization and the main secondary endpoint was the composite of cardiovascular death or HF hospitalization. For the later competing risk methods were used.
RESULTS
sNEP was measured in 1428 patients (age 67.7±12.7, 70.3% men, LVEF 35.8% ±14), 144 of which had a LVEF >57%. sNEP levels did not significantly differ between LVEF groups (p = 0.31). During a mean follow-up of 6±3.9 years, the primary endpoint occurred in 979 patients and the secondary composite endpoint in 714 (in 111 and 84 of the 144 patients with LVEF >57%, respectively). sNEP was significantly associated with both composite endpoints. Age- and sex- adjusted Cox regression analyses showed higher hazard ratios for sNEP in patients with LVEF >57%, both for the primary (HR 1.37 [1.16-1.61] vs. 1.04 [0.97-1.11]) and the secondary (HR 1.38 [1.21-1.55] vs. 1.11 [1.04-1.18]) composite endpoints.
CONCLUSIONS
sNEP prognostic value in patients with HF and LVEF >57% outperforms that observed in patients with lower LVEF. Precision medicine using sNEP may identify HF patients with preserved LVEF that may benefit from treatment with sacubitril/valsartan.
Identifiants
pubmed: 33989294
doi: 10.1371/journal.pone.0249674
pii: PONE-D-21-00228
pmc: PMC8121351
doi:
Substances chimiques
Aminobutyrates
0
Biomarkers
0
Biphenyl Compounds
0
sacubitril
17ERJ0MKGI
Valsartan
80M03YXJ7I
Neprilysin
EC 3.4.24.11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0249674Déclaration de conflit d'intérêts
A. Bayes-Genis has received speaker fees from Novartis; Julio Núñez has received speaker fees from Novartis, Vifor Pharma, Boehringer Ingelheim, Astra Zeneca, Rovi, and Novonordisk; A. Bayes-Genis and J. Lupón have applied for a patent for sNEP as prognostic biomarker and report a relationship with Critical Diagnostics. The rest of the authors have no conflicts of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials.
Références
FASEB J. 1989 Feb;3(2):145-51
pubmed: 2521610
JACC Heart Fail. 2020 Jan;8(1):70-80
pubmed: 31392960
J Am Heart Assoc. 2017 Aug 18;6(8):
pubmed: 28862951
Rev Esp Cardiol (Engl Ed). 2016 Jul;69(7):647-9
pubmed: 27264488
J Mol Biol. 2000 Feb 18;296(2):341-9
pubmed: 10669592
Circulation. 2020 Feb 4;141(5):352-361
pubmed: 31736342
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
J Am Soc Echocardiogr. 2005 Dec;18(12):1440-63
pubmed: 16376782
J Heart Lung Transplant. 2016 May;35(5):684-5
pubmed: 26830756
J Am Heart Assoc. 2019 Aug 6;8(15):e012943
pubmed: 31345101
Rev Esp Cardiol (Engl Ed). 2015 Dec;68(12):1075-84
pubmed: 26297179
Eur J Heart Fail. 2016 May;18(5):576
pubmed: 27135772
N Engl J Med. 2014 Sep 11;371(11):993-1004
pubmed: 25176015
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
J Am Coll Cardiol. 2015 Feb 24;65(7):657-65
pubmed: 25677426
JACC Heart Fail. 2015 Aug;3(8):641-4
pubmed: 26251092
JAMA. 2017 Aug 22;318(8):713-720
pubmed: 28829876
Eur J Heart Fail. 2016 Jan;18(1):89-93
pubmed: 26725876
J Am Coll Cardiol. 2016 Aug 9;68(6):639-653
pubmed: 27491909
Int J Cardiol. 2016 Oct 1;220:742-4
pubmed: 27393859
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819